Abstract：
UNASSIGNED: Knee osteoarthritis (KOA) is a leading cause of disability among older adults without a curative therapy available. The development of disease-modifying OA drugs based on intra-articular injection (IA) is drawing extensive attention for its advantages in bioavailability and reduced systemic exposure. Based on the newly revealed pathogenesis of OA, several experimental IA drugs are successful in preclinical studies; moreover, some of them are in different phases of randomized clinical trials, bringing new opportunities for disease modification of OA.
UNASSIGNED: This is a targeted literature review to summarize experimental IA drugs targeting cartilage repair, cellular homeostasis, cellular senescence, and pain control. We also introduced targeted gene/oligonucleotide products.
UNASSIGNED: Currently available therapeutics for KOA remain symptomatic relief and surgical replacement of damaged joints. Recently emerging experimental IA drugs are in different stages of development and are likely to enter practice in the near future and address many of the unmet needs. The major challenges for development of the new drugs are limited knowledge about the responsive subjects, heterogenicity of subjects and the complexity of the disease. Despite this, IA-based experimental drugs still hold great potential to be future disease-modifying treatments for their intrinsic advantages.
UNASSIGNED: This is a targeted literature review to summarize experimental IA drugs targeting cartilage repair, cellular homeostasis, cellular senescence, and pain control. We also introduced targeted gene/oligonucleotide products.
UNASSIGNED: Currently available therapeutics for KOA remain symptomatic relief and surgical replacement of damaged joints. Recently emerging experimental IA drugs are in different stages of development and are likely to enter practice in the near future and address many of the unmet needs. The major challenges for development of the new drugs are limited knowledge about the responsive subjects, heterogenicity of subjects and the complexity of the disease. Despite this, IA-based experimental drugs still hold great potential to be future disease-modifying treatments for their intrinsic advantages.
摘要：
■膝关节骨性关节炎（KOA）是导致老年人残疾的主要原因，而没有治愈性治疗。基于关节内注射（IA）的疾病缓解性OA药物的开发因其在生物利用度和减少全身暴露方面的优势而引起广泛关注。根据新揭示的OA发病机制，几种实验性IA药物在临床前研究中取得了成功；此外，其中一些处于随机临床试验的不同阶段，为OA的疾病改良带来新的机遇。
■这是一篇有针对性的文献综述，旨在总结针对软骨修复的实验IA药物，细胞内稳态,细胞衰老,疼痛控制。我们还引入了靶向基因/寡核苷酸产物。
■目前可用的KOA治疗方法仍然是症状缓解和手术置换受损关节。最近新兴的实验性IA药物处于不同的开发阶段，并且可能在不久的将来进入实践，并解决许多未满足的需求。新药开发的主要挑战是对反应对象的知识有限，受试者的异质性和疾病的复杂性。尽管如此,基于IA的实验药物由于其固有的优势，仍然具有很大的潜力成为未来的疾病修饰治疗方法。
■这是一篇有针对性的文献综述，旨在总结针对软骨修复的实验IA药物，细胞内稳态,细胞衰老,疼痛控制。我们还引入了靶向基因/寡核苷酸产物。
■目前可用的KOA治疗方法仍然是症状缓解和手术置换受损关节。最近新兴的实验性IA药物处于不同的开发阶段，并且可能在不久的将来进入实践，并解决许多未满足的需求。新药开发的主要挑战是对反应对象的知识有限，受试者的异质性和疾病的复杂性。尽管如此,基于IA的实验药物由于其固有的优势，仍然具有很大的潜力成为未来的疾病修饰治疗方法。
